InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,018.39
(
-0.34%
)
US TECH 100
17,006.40
(
0.86%
)
Dow Jones
37,903.29
(
0.23%
)
Brent Oil
84.31
(
0.92%
)
Bitcoin
57,680.44
(
-0.96%
)
Post# of 641959
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Covid19freak

Send PM Follow Ignore
Followers 10
Posts 1247
Boards Moderated 0
Alias Born 07/20/2020

Covid19freak

Re: None

Tuesday, 11/21/2023 3:43:42 PM

Tuesday, November 21, 2023 3:43:42 PM

Post# of 641959
ANVS $6.50 -Alzheimer & Parkinson trials both in Phase 3 with results expected in Q1 , market cap only 65 million .. this could be a 10 bagger on positive results

Annovis looks to advance pivotal Alzheimer’s and Parkinson’s drug studies
https://www.pharmaceutical-technology.com/news/annovis-looks-to-advance-pivotal-alzheimers-and-parkinsons-drug-studies/

Annovis Bio is working to progress its lead oral drug for Alzheimer’s disease (AD) and Parkinson’s disease (PD) studies as two trials evaluating the therapy’s potential reach the tail-end of their recruiting goals, CEO Maria Maccecchini, PhD, told Pharmaceutical Technology.

Data from both trials is expected in the first half of 2024.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up